To make this in silico comparison in our experimental study, we filtered TCGA data in order to keep only colon cancer samples from patients harbouring KRAS mutations and with wild-type BRAF. This led to a final cohort of n = 118 tumour samples and n = 304 normal tissues (cohort assembling and filtering procedures are detailed in Supplementary Materials, Section S2). This evidence concerns the gene KRAS and malignant colon neoplasm.